-
Blood testing in 2022 will provide a breakthrough in Alzheimer's disease and Parkinson's disease research
Time of Update: 2022-01-10
Quanterix, another testing and research company, said that the detection of specific types of tau in blood samples may better explain the development of this disease than amyloid .
-
Takeda's CMV drug Livtencity receives FDA approval and sales are expected to reach US$800 million
Time of Update: 2022-01-03
CompilationFan DongdongRecently, the US FDA has approved Takeda Livtencity (maribavir) to treat patients with cytomegalovirus (CMV) infection after transplantation in adults or children 12 years of age or older .
-
Significant progress in malignant pleural mesothelioma (MPM
Time of Update: 2021-06-01
com" target="_blank">/ --Ono Pharmaceutical recently announced that the Japanese regulatory agency has approved the anti-PD-1 therapy Opdivo (Odivo, generic name: nivolumab, nivolumab) combined with anti-CTLA-4 therapy Yervoy (ipilimumab, Yi Primoma) immunocombination therapy, the first-line treatment for patients with unresectable advanced or recurrent malignant pleural mesothelioma (MPM).
-
The first chronic kidney disease-related pruritus (CKD-aP) drug
Time of Update: 2021-04-19
Recently, the company and its partner Vifor Pharma jointly announced that the European Medicines Agency (EMA) has accepted a marketing authorization application (MAA) for Korsuva (CR845, difelikefalin) injection, which is used to treat chronic kidney disease-related itching in hemodialysis patients (CKD-aP).
-
Injection once a week! Noro and NORD long-acting human growth hormone have been approved clinically in China
Time of Update: 2021-01-12
Screenshot Source: CDE.com Somapacitan (Sogroya) is a novel, reversible human growth hormone derivative that binds to albumin and is modified by natural hGH to enhance its binding to endogenous plasma protein albumin, thus prolonging the half-life of molecules.
-
Express . . . Treatment of rare immune diseases, precision anti-cancer therapy Phase 2 data positive
Time of Update: 2020-07-22
▎ today, blueprint medicine announced that its oral kit and pdapritinib, an oral inhibitor of PDGFR α, have significantly improved the comprehensive symptoms of patients with systemic mastocytosis (SM) in the phase II clinical trial of Pioner in the treatment of systemic mastocytosis (SM).
-
FDA grants Roche's preferred review
Time of Update: 2020-06-07
, Roche announced that the u.S FDA (http:// has accepted and qualified for priority review of new drug (http:// About Risdiplam Risdiplam is an mRNA shear modifier for the SMN2 gene for spin
-
Newest! National Health and Health Commission named these drugs: oseltamivir, Lianhua Qingwen
Time of Update: 2019-11-15
Finishing: Ania These drugs are about to enter the peak sales season On the evening of November 13, the national health and Health Commission issued the notice on doing well the medical work of influe
-
Baiji Shenzhou Q3 performance: Revenue: 50.14 million US dollars; R & D Investment: 236.97 million US dollars
Time of Update: 2019-11-13
On November 13, 2019, Baiji Shenzhou company today announced its recent business highlights, expected milestones, and financial results for the third quarter of 2019 Mr Ou Lei Qiang, founder, CEO and
-
The world's first Ebola vaccine! Ervebo of Merck obtains EU approval
Time of Update: 2019-11-12
Fan Dongdong 11 November Ervebo is composed of modified vesicular stomatitis virus (VSV) and important glycoprotein on the surface of Ebola virus VSV can sicken some domestic animals, but it is harmle
-
Overseas medical information Morning Post
Time of Update: 2015-11-26
The European Commission has the conditions to approve the use of aninjin CD19 / CD3 bispecific antibody blincyto (blindumoma b) for the treatment of adult Philadelphia chromosome negative relapse / re
-
Big data becomes "catalyst" for drug innovation
Time of Update: 2015-05-05
The 2015 China (Beijing) International Technology Transfer Conference is the most fashionable vocabulary at present Because of its ability to quickly obtain valuable information from various types of
-
Ocugen retinitis pigmentosa drug ocu100 obtained the FDA orphan drug qualification
Time of Update: 2014-06-09
TSID = 28 & region?
